Health
New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer. – Brinkwire
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
General21 hours agoKim Nok-wan sentenced to life in prison for sexual abuse and exploitation of hundreds of people in South Korea
-
Noosa News16 hours agoQueensland teachers strike for second time this year after rejecting 8 per cent wage rise
-
General23 hours agoKangaroos star Ash Riddell wins AFLW best and fairest award
-
General16 hours agoVictorian government blocked fire service from pursuing US giant over PFAS contamination